Electra Therapeutics CFO holds 612K stock options

Electra Therapeutics discloses its CFO’s initial option holdings, detailing two large option grants with long-dated expirations and staged vesting.

Rhea-AI Filing Summary

Electra Therapeutics, Inc. (ETRA) reported initial holdings for its Chief Financial Officer Christopher William Clark, consisting of two employee stock options over common stock. One option covers 319,202 shares at $4.96 per share, expiring February 12, 2036, and is early exercisable with vesting beginning December 1, 2025. A second option covers 292,781 shares at $15.00 per share, expiring September 16, 2036, with monthly vesting commencing September 17, 2026.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Clark Christopher William

Role Chief Financial Officer

Type	Security	Shares	Price	Value
holding	Employee Stock Option (right to buy) F1	--	--	--
holding	Employee Stock Option (right to buy) F2	--	--	--

Holdings After Transaction: Employee Stock Option (right to buy) — 611,983 contracts (Direct)

Footnotes (2)

1. F1. 1/4th of the total shares subject to this option shall vest one year after December 1, 2025, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
2. F2. 1/48th of the total shares subject to this option shall vest monthly commencing from September 17, 2026.

Key Figures

Option 1 underlying shares: 319,202 shares Option 1 exercise price: $4.96 per share Option 1 expiration: February 12, 2036 +3 more

6 metrics

Option 1 underlying shares 319,202 shares Employee stock option over common stock held by the CFO

Option 1 exercise price $4.96 per share Exercise price for 319,202-share option expiring February 12, 2036

Option 1 expiration February 12, 2036 Expiration date of the 319,202-share employee stock option

Option 2 underlying shares 292,781 shares Second employee stock option over common stock held by the CFO

Option 2 exercise price $15.00 per share Exercise price for 292,781-share option expiring September 16, 2036

Option 2 expiration September 16, 2036 Expiration date of the 292,781-share employee stock option

Key Terms

Employee Stock Option (right to buy), early exercisable, right of repurchase, vest

4 terms

Employee Stock Option (right to buy) financial

"The security title is Employee Stock Option (right to buy) over common stock"

early exercisable financial

"The shares subject to this option are early exercisable, subject to repurchase"

right of repurchase financial

"Early exercisable, subject to the Issuer's right of repurchase"

vest financial

"1/4th vests one year after December 1, 2025 and 1/48th monthly thereafter"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider position does the Form 3 report for ETRA's Christopher William Clark?

The Form 3 reports that Christopher William Clark is the Chief Financial Officer of Electra Therapeutics, Inc. and discloses his initial holdings of two employee stock options over the company’s common stock.

What is the size and strike price of the first option reported for ETRA's CFO?

The first employee stock option for ETRA’s CFO covers 319,202 shares of common stock with an exercise price of $4.96 per share and an expiration date of February 12, 2036.

How does the first ETRA option held by the CFO vest?

For the first option, 1/4 of the total shares vest one year after December 1, 2025, and 1/48 of the total shares then vest on each monthly anniversary. The option is early exercisable and subject to the issuer’s right of repurchase.

What are the terms of the second employee stock option reported for ETRA's CFO?

The second employee stock option covers 292,781 shares of common stock at an exercise price of $15.00 per share, with an expiration date of September 16, 2036, and 1/48 of the shares vest monthly commencing from September 17, 2026.

Does the Form 3 for ETRA report any insider share purchases or sales?

No insider share purchases or sales are reported. The Form 3 lists holdings of employee stock options for the CFO, rather than buy or sell transactions in the company’s common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/18/2026 - 08:25 PM Accepted by SEC EDGAR 09/18/2026 - 04:16 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Clark Christopher William

(Last) (First) (Middle)

C/O ELECTRA THERAPEUTICS, INC.

230 E GRAND AVENUE, SUITE S-100

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
09/18/2026

3. Issuer Name and Ticker or Trading Symbol
Electra Therapeutics, Inc. [ ETRA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	(1)	02/12/2036	Common Stock	319,202	$4.96	D
Employee Stock Option (right to buy)	(2)	09/16/2036	Common Stock	292,781	$15	D

Explanation of Responses:

1. 1/4th of the total shares subject to this option shall vest one year after December 1, 2025, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.

2. 1/48th of the total shares subject to this option shall vest monthly commencing from September 17, 2026.

	/s/ Jamie Kitano, Attorney-in-Fact	09/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)